CVS Health Reports Record Fourth Quarter And Full Year Results For 2016; Confirms 2017 EPS Guidance

Go back to CVS Health Reports Record Fourth Quarter And Full Year Results For 2016; Confirms 2017 EPS Guidance

CVS Health (CVS) PT Raised to $89 at UBS

February 10, 2017 8:51 AM EST

UBS analyst Michael Cherny reiterates Buy rating and raises price target on CVS Health Corp. (NYSE: CVS) to $89 (from $88.50), suggesting the companys continued PBM net new business is offset by ongoing weakness in retail.

Cherny comments, "CVS 4Q had a number of... More

CVS Health (CVS) PT Lowered to $84 at Evercore ISI; Keeps 'Buy'

February 9, 2017 12:11 PM EST

Evercore ISI lowered its price target on CVS Health (NYSE: CVS) to $84.00 (from $91.50) while maintaining a Buy rating. The analyst said management did an admirable job on the DIR fee issue and a reasonable job on gross to net / rebates.

Analyst Ross Muken commented, "While the quarter proved generally uneventful and guidance was reiterated on the surface (albeit some moving parts below dollar profit... More

CVS Health (CVS) Tops Q4 EPS by 4c; Confirms Outlook

February 9, 2017 6:56 AM EST

CVS Health (NYSE: CVS) reported Q4 EPS of $1.71, $0.04 better than the analyst estimate of $1.67. Revenue for the quarter came in at $46 billion versus the consensus estimate of $46.5 billion.

Net revenues increased 11.7% to $46.0 billionOperating profit in line with Company\'s expectationsGAAP... More